RGLS Valuation
Regulus Therapeutics Inc
$
7.920
- Overview
- Forecast
- Valuation
RGLS Relative Valuation
RGLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGLS is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for RGLS's competitors is 110.97, providing a benchmark for relative valuation. Regulus Therapeutics Inc Corp (RGLS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
WMT
Walmart Inc
96.915
USD
-0.90%
MSFT
Microsoft Corp
455.230
USD
-0.64%
META
Meta Platforms Inc
639.560
USD
+0.39%
NVDA
NVIDIA Corp
136.595
USD
+1.65%
TSLA
Tesla Inc
344.620
USD
+0.23%
XOM
Exxon Mobil Corp
104.820
USD
-0.12%
ORCL
Oracle Corp
160.100
USD
-0.13%
AMZN
Amazon.com Inc
202.870
USD
-0.59%
AVGO
Broadcom Inc
234.840
USD
+1.36%
AAPL
Apple Inc
203.070
USD
-1.83%
FAQ
Is Regulus Therapeutics Inc (RGLS) currently overvalued or undervalued?
Regulus Therapeutics Inc (RGLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 599.27. The fair price of Regulus Therapeutics Inc (RGLS) is between NaN to NaN according to relative valuation methord.
What is Regulus Therapeutics Inc (RGLS) fair value?
How does RGLS's valuation metrics compare to the industry average?
What is the current P/B ratio for Regulus Therapeutics Inc (RGLS) as of May 21 2025?
What is the current FCF Yield for Regulus Therapeutics Inc (RGLS) as of May 21 2025?
What is the current Forward P/E ratio for Regulus Therapeutics Inc (RGLS) as of May 21 2025?